Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Cirugía para la epilepsia
Siobhan West, Sarah J Nevitt, Jennifer Cotton, Sacha Gandhi, Jennifer Weston, Ajay Sudan, Roberto Ramirez, Richard Newton | 25 junio 2019

Topics

Temas

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 IVIg versus placebo, Outcome 1 50% or greater reduction in seizure frequency for drug‐resistant epilepsy, ITT analysis.
Figuras y tablas -
Analysis 1.1

Comparison 1 IVIg versus placebo, Outcome 1 50% or greater reduction in seizure frequency for drug‐resistant epilepsy, ITT analysis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 IVIg versus placebo, Outcome 2 50% or greater reduction in seizure frequency for drug‐resistant epilepsy, per‐protocol.
Figuras y tablas -
Analysis 1.2

Comparison 1 IVIg versus placebo, Outcome 2 50% or greater reduction in seizure frequency for drug‐resistant epilepsy, per‐protocol.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 IVIg versus placebo, Outcome 3 50% or greater reduction in seizure frequency for drug‐resistant epilepsy, best‐case.
Figuras y tablas -
Analysis 1.3

Comparison 1 IVIg versus placebo, Outcome 3 50% or greater reduction in seizure frequency for drug‐resistant epilepsy, best‐case.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 IVIg versus placebo, Outcome 4 50% or greater reduction in seizure frequency for drug‐resistant focal epilepsy, ITT analysis.
Figuras y tablas -
Analysis 1.4

Comparison 1 IVIg versus placebo, Outcome 4 50% or greater reduction in seizure frequency for drug‐resistant focal epilepsy, ITT analysis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 IVIg versus placebo, Outcome 5 50% or greater reduction in seizure frequency for drug‐resistant focal epilepsy, per‐protocol.
Figuras y tablas -
Analysis 1.5

Comparison 1 IVIg versus placebo, Outcome 5 50% or greater reduction in seizure frequency for drug‐resistant focal epilepsy, per‐protocol.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 IVIg versus placebo, Outcome 6 50% or greater reduction in seizure frequency for drug‐resistant focal epilepsy, best‐case.
Figuras y tablas -
Analysis 1.6

Comparison 1 IVIg versus placebo, Outcome 6 50% or greater reduction in seizure frequency for drug‐resistant focal epilepsy, best‐case.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 IVIg versus placebo, Outcome 7 Global assessment for drug‐resistant epilepsy, ITT analysis.
Figuras y tablas -
Analysis 1.7

Comparison 1 IVIg versus placebo, Outcome 7 Global assessment for drug‐resistant epilepsy, ITT analysis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 IVIg versus placebo, Outcome 8 Global assessment for drug‐resistant epilepsy, per‐protocol.
Figuras y tablas -
Analysis 1.8

Comparison 1 IVIg versus placebo, Outcome 8 Global assessment for drug‐resistant epilepsy, per‐protocol.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 IVIg versus placebo, Outcome 9 Global assessment for drug‐resistant epilepsy, best‐case.
Figuras y tablas -
Analysis 1.9

Comparison 1 IVIg versus placebo, Outcome 9 Global assessment for drug‐resistant epilepsy, best‐case.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Summary of findings for the main comparison. IVIg compared to placebo for drug‐resistant epilepsy

IVIg compared to placebo for drug‐resistant epilepsy

Patient or population: patients with drug‐resistant epilepsy
Settings: three participating hospitals ‐ Ottignies (Belgium), Zurich (Switzerland) and Kehl‐Kork (Germany)
Intervention: IVIg
Comparison: placebo

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Placebo

IVIg

Seizure freedom

Not reported

Satisfactory seizure control
50% or greater reduction in seizure frequency for drug‐resistant epilepsy

278 per 1000

525 per 1000
(236 to 1000)

RR 1.89
(0.85 to 4.21)

58
(1 study)

⊕⊕⊝⊝
low1,2

Incidence of adverse or harmful effects

Not reported

Global assessment

167 per 1000

548 per 1000
(188 to 1000)

RR 3.29
(1.13 to 9.57)

60
(1 study)

⊕⊕⊝⊝
low1,2

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio

GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low certainty: We are very uncertain about the estimate.

1 Unclear risk of selection bias: no information was obtained on generation of the random sequence or concealment of allocation of the randomisation.
2 More trials and participants are needed to allow more precise estimation of the treatment effects of IVIg.

Figuras y tablas -
Summary of findings for the main comparison. IVIg compared to placebo for drug‐resistant epilepsy
Ir a la tabla de la revisión
Comparison 1. IVIg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 50% or greater reduction in seizure frequency for drug‐resistant epilepsy, ITT analysis Show forest plot

1

61

Risk Ratio (M‐H, Fixed, 95% CI)

1.76 [0.79, 3.93]

2 50% or greater reduction in seizure frequency for drug‐resistant epilepsy, per‐protocol Show forest plot

1

58

Risk Ratio (M‐H, Fixed, 95% CI)

1.89 [0.85, 4.21]

3 50% or greater reduction in seizure frequency for drug‐resistant epilepsy, best‐case Show forest plot

1

61

Risk Ratio (M‐H, Fixed, 95% CI)

2.01 [0.91, 4.43]

4 50% or greater reduction in seizure frequency for drug‐resistant focal epilepsy, ITT analysis Show forest plot

1

49

Risk Ratio (M‐H, Fixed, 95% CI)

3.08 [0.84, 11.34]

5 50% or greater reduction in seizure frequency for drug‐resistant focal epilepsy, per‐protocol Show forest plot

1

46

Risk Ratio (M‐H, Fixed, 95% CI)

3.35 [0.91, 12.30]

6 50% or greater reduction in seizure frequency for drug‐resistant focal epilepsy, best‐case Show forest plot

1

49

Risk Ratio (M‐H, Fixed, 95% CI)

3.57 [0.98, 13.00]

7 Global assessment for drug‐resistant epilepsy, ITT analysis Show forest plot

1

61

Risk Ratio (M‐H, Fixed, 95% CI)

3.21 [1.10, 9.36]

8 Global assessment for drug‐resistant epilepsy, per‐protocol Show forest plot

1

60

Risk Ratio (M‐H, Fixed, 95% CI)

3.29 [1.13, 9.57]

9 Global assessment for drug‐resistant epilepsy, best‐case Show forest plot

1

61

Risk Ratio (M‐H, Fixed, 95% CI)

3.35 [1.15, 9.73]
Figuras y tablas -
Comparison 1. IVIg versus placebo
Ir a la tabla de la revisión